Related Experiment Video
Updated: May 29, 2026
05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Off-label intravenous thrombolysis in acute stroke
M Guillan1, A Alonso-Canovas, J Garcia-Caldentey
1Stroke Unit, Department of Neurology, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain.
European Journal of Neurology
|September 8, 2011
Summary
Off-label use of intravenous tissue plasminogen activator (IV-tPA) for stroke treatment is safe and effective. This study found no significant differences in outcomes for patients treated outside of standard IV-tPA guidelines.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Intravenous tissue plasminogen activator (IV-tPA) is a critical treatment for acute ischemic stroke.
- Current licensing restrictions limit the use of IV-tPA in certain patient populations.
- Recent literature has explored the potential benefits of expanding IV-tPA eligibility.
Purpose of the Study:
- To assess the safety and effectiveness of off-label IV-tPA administration in clinical stroke settings.
- To compare outcomes between patients treated within on-label criteria and those treated off-label.
Main Methods:
- Retrospective analysis of 505 patients treated with IV-tPA at a dedicated Stroke Unit.
- Patients categorized into on-label (OnLG) and off-label (OffLG) groups based on licensing criteria.
- Primary outcomes included symptomatic intracranial hemorrhage (sICH), major systemic hemorrhages, modified Rankin Scale (mRS) at 3 months, and mortality rate.
Main Results:
- 269 patients were in the OnLG and 236 in the OffLG, with OffLG criteria including age >80, treatment >3h, prior anticoagulation, and NIHSS >25.
- No significant differences in sICH rates (OnLG 2.2% vs. OffLG 1.6%) or 3-month mortality (11.1% vs. 19%) between groups.
- Multivariate analysis revealed no significant differences in functional independence (mRS <3: 64.3% vs. 50.4%) at 3 months.
Conclusions:
- Off-label use of IV-tPA demonstrates comparable safety and efficacy to on-label use.
- Current licensing restrictions for IV-tPA may be unnecessarily limiting.
- Intravenous thrombolysis can be safely and effectively administered beyond established label indications.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.